Universal reference book for medicines
Product name: ECOFURIL ® (ECOFURIL)

Active substance: nifuroxazide

Type: Intestinal antiseptic.
Antidiarrhoeal drug
Manufacturer: АВВА РУС (Russia)
Composition, form of production and packaging
?
Capsules hard gelatinous, №0, yellow; the contents of the capsules are a yellow powder.
1 caps.

nifuroxazide 100 mg

Excipients: lactulose - 300 mg, microcrystalline cellulose - 23 mg, potato starch - 9 mg, magnesium stearate - 4 mg, sucrose - to obtain a mass of the contents of the capsule 460 mg.

The composition of the hard gelatin capsule: gelatin - up to 100%, water - 14-15%, dye quinoline yellow - 0.5834%, dye sunset yellow - 0.0026%, titanium dioxide - 0.974%.

10 pieces.
- packings cellular planimetric (3) - packs cardboard.
30 pcs.
- plastic bottles (1) - packs of cardboard.
30 pcs.
- vials polymeric (1) - packs cardboard.
?
Capsules hard gelatinous, №00, with a yellow body and an orange lid; the contents of the capsules are a yellow powder.
1 caps.

nifuroxazide 200 mg

Excipients: lactulose - 300 mg, microcrystalline cellulose - 58 mg, potato starch - 18 mg, magnesium stearate - 6 mg, sucrose - until the mass of the contents of the capsule is 630 mg.

The composition of the hard gelatin capsule: gelatin - up to 100%, water - 14-15%;
lid: dye crimson [Ponso 4R] - 0.079801%, dye blue patented - 0.00165%, dye sunset - 0.093301%, titanium dioxide - 0.813158%; body: dye quinoline yellow - 0.583356%, dye sunset - 0.002565%, titanium dioxide - 0.974035%.
5 pieces.
- packings cellular planimetric (6) - packs cardboard.
30 pcs.
- plastic bottles (1) - packs of cardboard.
30 pcs.
- vials polymeric (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2016.

PHARMACHOLOGIC EFFECT

A broad-spectrum antimicrobial agent is a derivative of 5-nitrofuran for the treatment of gastrointestinal infections.

Nifuroxazide blocks the activity of dehydrogenases and depresses the respiratory chains, the cycle of tricarboxylic acids and other biochemical reactions in the bacterial cell.
It destroys the membranes of sensitive bacteria, reduces the production of toxins by microorganisms. Activates immunity, increases the activity of phagocytes and the complement titer.
Effective against gram-positive microorganisms: Staphylococcus spp., Streptococcus spp .;
Gram-negative microorganisms: Salmonella spp., Klebsiella spp., Enterobacter spp., Escherichia coli, Shigella spp., Proteus spp., Haemophilus influenzae, Campilobacter spp., Edwarsiella spp., Citrobacter spp., Vibrio cholerae, Yersinia enterocolitica.
Nifuroxazide does not affect the state of normal microflora of the human intestine.
With acute bacterial diarrhea, eubiosis of the intestine is restored. When infected with enterotrophic viruses prevents the development of bacterial superinfection.
PHARMACOKINETICS

After oral administration, nifuroxazide is practically not absorbed from the digestive tract and does not have a systemic effect.
Antibacterial activity against sensitive species of bacteria manifests only in the lumen of the intestine. In unchanged form is excreted by the intestine. The speed of elimination depends on the dose of the drug and the motility of the gastrointestinal tract.
INDICATIONS

- acute and chronic diarrhea of ​​infectious genesis (without signs of helminthic invasion);

- chronic colitis and enterocolitis.

DOSING MODE

The drug is taken orally.

Adults and children over 7 years of age are prescribed 2 caps.
100 mg or 1 caps. 200 mg 4 times / day (800 mg / day).
Children aged 3-7 years are assigned 2 caps.
100 mg or 1 caps. 200 mg 3 times / day (600 mg / day).
The duration of therapy with nifuroxazide is no more than 7 days.

SIDE EFFECT

Possible: allergic reactions.

CONTRAINDICATIONS

- hypersensitivity to nifuroxazide, other components of the drug, other derivatives of 5-nitrofuran;

- deficiency of sugar / isomaltase, intolerance to fructose, glucose-galactose malabsorption;

- Children's age of up to 3 years (for this form).

PREGNANCY AND LACTATION

There are no data on adverse effects on the fetus during pregnancy.
If necessary, with caution, the drug can be given to pregnant women and women breastfeeding.
APPLICATION FOR CHILDREN

Contraindicated use of the drug in childhood to 3 years (for this form).

SPECIAL INSTRUCTIONS

When treating diarrhea concomitantly with nifuroxazide therapy, rehydration therapy (oral or intravenous) should be performed in accordance with the patient's condition and duration of diarrhea.

During therapy with nifuroxazide, alcohol intake is not allowed.

Impact on the ability to drive vehicles and manage mechanisms

The drug does not adversely affect the ability to drive vehicles and / or other mechanisms.

OVERDOSE

Specific symptoms of overdose are not described.

Treatment: standard emergency measures are recommended.

DRUG INTERACTION

No data on the interaction of nifuroxazide with other drugs have been published.

TERMS OF RELEASE FROM PHARMACY

The drug is dispensed without a prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored in a place protected from moisture and light, inaccessible to children at a temperature of no higher than 25 ° C.
Shelf life - 5 years. Do not use after expiry date.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!